RLX expression was detected in tumors treated with either RdB/IL12/GMCSF-RLX monotherapy or combination of RdB/IL12/GMCSF-RLX + αPD-1 (Fig. 3C), implying that all therapeutic genes can be expressed effectively by oncolytic Ad in tumor tissues. This evidence concerns the gene CSF2 and neoplasm.